Security key
H0036K147
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT)
CUSIP: H0036K147
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Shares, par value CHF 0.08 per share
- Total 13F shares
- 54,846,167
- Total 13F value
- $77,332,587
- Share change
- -1,623,520
- Put/Call ratio
- 152%
- SEC-reported price per share
- $1.41
- Number of holders
- 82
- Value change
- -$2,528,133
- Number of buys
- 38
- Number of sells
- 33
- Shares outstanding
- 128,459,465
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
82
Top holders
10
ADCT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2025
Previous quarter: Q4 2024
ADC Therapeutics SA SEC filings
ADC Therapeutics SA company facts
Broader feeds
Reporting periods
Holder history for CUSIP H0036K147
Recent filing periods:
Ownership snapshot
Top reported holders of ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
Redmile Group, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2024
13F
13D/G
Lead comparable stake: 5%
13D/G row: BlackRock, Inc.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
5%
Redmile Group, LLC
12%
Prosight Management, LP
7.4%
ORBIMED ADVISORS LLC
4.6%
MORGAN STANLEY
3.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
5%
from 13D/G
|
$9,973,595
5,011,857 shares
|
— | 31 Dec 2024 |
| Redmile Group, LLC |
13F
Company
|
12%
|
$31,176,795
15,666,731 shares
|
— | 31 Dec 2024 |
| Prosight Management, LP |
13F
Company
|
7.4%
|
$18,934,850
9,515,000 shares
|
— | 31 Dec 2024 |
| ORBIMED ADVISORS LLC |
13F
Company
|
4.6%
|
$11,877,217
5,968,451 shares
|
— | 31 Dec 2024 |
| MORGAN STANLEY |
13F
Company
|
3.1%
|
$7,872,781
3,956,172 shares
|
— | 31 Dec 2024 |
| Woodline Partners LP |
13F
Company
|
1.5%
|
$3,848,164
1,933,751 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
82
Shares
54,846,167
Rows available
82
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
82
Q1 2025 holders
82
Holder diff
0
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend